
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Corsair Completes Preclinical Program for Treprostinil Prodrug Patch
Details : TRX-248 transdermal system, a once-daily transdermal patch delivering treprostinil, a prostaglandin mimetic, for the treatment of Pulmonary Arterial Hypertension (PAH).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Treprostinil Prodrug
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : InstantGMP
Deal Size : Undisclosed
Deal Type : Partnership
Corsair Pharma Partners with InstantGMP® to Ensure Quality for Clinical Trials
Details : The partmership aims to create improved treatment options for patients with complex medical needs, including PAH treatment with its first product candidate CO-254, a prodrug of treprostinil.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 28, 2025
Lead Product(s) : Treprostinil Prodrug
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : InstantGMP
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Treprostinil Prodrug
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Junson Capital
Deal Size : $23.0 million
Deal Type : Series B Financing
Details : The proceeds will support the clinical advancement of Corsair’s lead product candidate, a prodrug of treprostinil delivered in a proprietary transdermal patch to treat Pulmonary Arterial Hypertension (PAH).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 20, 2023
Lead Product(s) : Treprostinil Prodrug
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Junson Capital
Deal Size : $23.0 million
Deal Type : Series B Financing
